Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 20, 2023 - Issue 8: Overcoming Biological Barriers: Respiratory drug delivery
Submit an article Journal homepage
3,184
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The importance of dissolution for orally inhaled drug products: pharmaceutical, regulatory, and clinical considerations

Karin Sombya King’s College London, Institute of Pharmaceutical Science, London, UK;b Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Martin Hingleb Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Ivana Tomicb Novartis Pharma AG, Basel, SwitzerlandView further author information
&
Ben Forbesa King’s College London, Institute of Pharmaceutical Science, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8193-6107View further author information
ORCID Icon
Pages 1033-1036 | Received 23 Dec 2022, Accepted 18 Apr 2023, Published online: 24 Apr 2023

References

  • Riley T, Christopher D, Arp J, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS Pharm Sci Tech. 2012 Sep;13(3):978–989.
  • Price R, Shur J, Ganley W, et al. Development of an aerosol dose collection apparatus for in vitro dissolution measurements of orally inhaled drug products. AAPS J. 2020 Mar;22(2). DOI:10.1208/s12248-020-0422-y.
  • Hochhaus G, Chen M-J, Kurumaddali A, et al. Can pharmacokinetic studies assess the pulmonary fate of dry powder inhaler formulations of fluticasone propionate? AAPS J. 2021 May;23(3). DOI:10.1208/s12248-021-00569-x.
  • Hastedt JE, Bäckman P, Cabal A, et al. iBCS: 1. principles and framework of an inhalation-based biopharmaceutics classification system. Mol Pharm. 2022 May;19(7):2032–2039.
  • McAllister M, Flanagan T, Cole S, et al. Developing Clinically Relevant Dissolution Specifications (CRDSs) for oral drug products: virtual webinar series. Pharmaceutics. 2022 May;14(5):1010.
  • Mercuri A, Fotaki N. In Vitro Dissolution for Inhalation Products. In In Vitro drug release testing of special dosage forms. Wiley; 2019. DOI:10.1002/9781118675748.ch5.
  • Gerde P, Malmlöf M, Havsborn L, et al. DissolvIt: an in vitro method for simulating the dissolution and absorption of inhaled dry powder drugs in the lungs. Assay Drug Dev Technol. 2017 Feb;15(2):77–88.
  • Sonvico F, Chierici V, Varacca G, et al. RespicellTM: an innovative dissolution apparatus for inhaled products. Pharmaceutics. 2021 Oct;13(10):1541.
  • Franek F, Fransson R, Thörn H, P. Bäckman P, Andersson U, and Tehler U. Ranking in vitro dissolution of inhaled micronized drug powders including a candidate drug with two different particle sizes. Mol Pharm. 2018 Nov;15(11):5319–5326. DOI:10.1021/acs.molpharmaceut.8b00796.
  • Ruzycki CA, Murphy B, Nathoo H, et al. Combined in vitro-in silico approach to predict deposition and pharmacokinetics of budesonide dry powder inhalers. Pharm Res. 2020;37(10):209.
  • Hassoun M, Malmlöf M, Scheibelhoferd O, et al. Use of PBPK modeling to evaluate the performance of DissolvIt, a biorelevant dissolution assay for orally inhaled drug products. Mol Pharmaceut. 2019;16(3):1245–1254.
  • Floroiu A, Klein M, Krämer J, et al. Towards standardized dissolution techniques for in vitro performance testing of dry powder inhalers. In: Dissolution Technologies. Aug 1, 2018. Vol. 253. Dissolution Technologies Inc. DOI:10.14227/DT250318P6.
  • Forbes B, Richer NH, Buttini F. Dissolution: a critical performance characteristic of inhaled products? Pulm Drug Deliv. 2015;223–240. DOI:10.1002/9781118799536.ch10.
  • Forbes B, Bäckman P, Christopher D, et al. In Vitro testing for orally inhaled products: developments in science-based regulatory approaches. Aaps J. 2015 Jul;17(4):837–852. DOI:10.1208/s12248-015-9763-3.
  • Allen A, Bal J, Moore A, et al. Bioequivalence and dose proportionality of inhaled fluticasone furoate. J Bioequivalence Bioavailab. 2014;6(1):24–32.
  • Bäckman P, Tehler U, Olsson B. Predicting exposure after oral inhalation of the selective glucocorticoid receptor modulator, AZD5423, based on dose, deposition pattern, and mechanistic modeling of pulmonary disposition. J Aerosol Med Pulm Drug Deliv. 2017;30(2):108–117.
  • Bäckman P, Cabal A, Clark A, et al. iBCS. 2: mechanistic modeling of pulmonary availability of inhaled drugs versus critical product attributes. Mol Pharm. 2022 May;19(7):2040–2047.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.